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ransforming growth factor-
 
 
 
s (TGF-
 
 
 
s) are pleiotro-
pic cytokines involved in development and mainte-
nance of the nervous system. In several neural lesion
paradigms, TGF-
 
 
 
1 exerts potent neuroprotective effects.
Neurons treated with TGF-
 
 
 
1 activated the canonical
TGF-
 
 
 
 receptor I/activin-like kinase receptor 5 (ALK5)
pathway. The transcription factor nuclear factor-
 
 
 
B (NF-
 
 
 
B)
plays a fundamental role in neuroprotection. Treatment
with TGF-
 
 
 
1 enhanced NF-
 
 
 
B activity in gelshift and re-
porter gene analyses. However, ectopic expression of a
constitutively active ALK5 failed to mimic these effects.
T
 
ALK1 has been described as an alternative TGF-
 
 
 
 receptor
in endothelial cells. Interestingly, we detected signiﬁcant
basal expression of ALK1 and its injury-induced up-regu-
lation in neurons. Treatment with TGF-
 
 
 
1 also induced a
pronounced increase in downstream Smad1 phosphory-
lation.  Overexpression of a constitutively active ALK1
mimicked the effect of TGF-
 
 
 
1 on NF-
 
 
 
B activation and
neuroprotection. Our data suggest that TGF-
 
 
 
1 simulta-
neously activates two distinct receptor pathways in neurons
and that the ALK1 pathway mediates TGF-
 
 
 
1–induced
NF-
 
 
 
B survival signaling.
 
Introduction
 
Transforming growth factor-
 
 
 
s (TGF-
 
 
 
s) are pleiotropic cy-
tokines implicated in control of cell growth, differentiation,
inflammation, and apoptosis. The mammalian TGF-
 
 
 
 iso-
forms 2 and 3 are expressed in neurons and glial cells of the
central nervous system, whereas TGF-
 
 
 
1 expression is largely
confined to the meninges and choroid plexus (Flanders et al.,
1991). Expression of TGF-
 
 
 
2 and -
 
 
 
3 are mainly regulated by
hormonal and developmental signals (Flanders et al., 1998). In
contrast, TGF-
 
 
 
1 expression and release increases signifi-
cantly in response to central nervous system lesions, with acti-
vated microglia/macrophages being a major source (Lindholm
et al., 1992). TGF-
 
 
 
1 has been shown to protect cultured neu-
rons from hypoxic (Prehn et al., 1993a), excitotoxic (Prehn
and Krieglstein, 1994), apoptotic (Prehn et al., 1994), meta-
bolic (Krieglstein et al., 1995), and toxic peptide-induced in-
jury (Meucci and Miller, 1996; Prehn et al., 1996; Ren and
Flanders, 1996). In vivo, administration of recombinant TGF-
 
 
 
1
or gene delivery of TGF-
 
 
 
1 potently protects animals against
brain injury mediated by ischemic (McNeill et al., 1994; Zhu
et al., 2002), excitotoxic (Ruocco et al., 1999), and oxidative
stress (Henrich-Noack et al., 1996). Moreover, lack of TGF-
 
 
 
1
expression in neonatal Tgfb1
 
 
 
/
 
 
 
 mice results in a widespread
increase in degenerating neurons and a prominent microgliosis
(Brionne et al., 2003).
Neuroprotection by TGF-
 
 
 
1 has been shown to involve
the up-regulation of the antiapoptotic Bcl-2 family proteins
Bcl-2 and Bcl-xL (Prehn et al., 1994, 1996; Kim et al., 1998).
Both are target genes of the transcription factor nuclear factor-
 
 
 
B (NF-
 
 
 
B; Lee et al., 1999; Tamatani et al., 1999; Bui et al.,
2001). Indeed, a recent paper has demonstrated that TGF-
 
 
 
1
activates NF-
 
 
 
B in neurons and that neuroprotection elicited
by TGF-
 
 
 
1 requires NF-
 
 
 
B activation (Zhu et al., 2004). Of
note, these observations sharply contrast with effects of TGF-
 
 
 
1 described in other cell types and organ systems. For exam-
ple, TGF-
 
 
 
1 has been shown to inhibit NF-
 
 
 
B activation and to
trigger cell death in B cells and hepatocytes (Oberhammer et al.,
1992; Arsura et al., 1996).
The present work will aid to provide an explanation for
this apparent discrepancy. We demonstrate that TGF-
 
 
 
1 is able
to activate two distinct TGF-
 
 
 
 type I receptors and signal trans-
duction pathways in neurons: the canonical activin-like kinase 5
(ALK5)/Smad2/3 pathway and a novel, ALK1/Smad1/5-regu-
lated pathway. Furthermore, we demonstrate that signaling
through ALK1 mediates the activation of the antiapoptotic
NF-
 
 
 
B pathway.
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cysteine; T
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, transforming growth factor-
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Results
 
ALK1 receptor is expressed in neurons 
and the level of expression increases 
during excitotoxic and ischemic injury
 
TGF-
 
 
 
s signal through a family of serine/threonine receptor ki-
nases. Binding of TGF-
 
 
 
s to the constitutively active type II re-
ceptor initiates the recruitment of type I receptors, which subse-
quently become phosphorylated and transduce the signals into
the cytosol (Shi and Massague, 2003). TGF-
 
 
 
 receptor type II
(T
 
 
 
RII) and T
 
 
 
RI/ALK5 have been shown to be expressed in
the central nervous system and in cultured neurons (Bottner et
al., 1996). Recent studies have demonstrated the existence of an
alternative TGF-
 
 
 
 type I receptor, ALK1 (Lux et al., 1999). To
investigate the contribution of different TGF-
 
 
 
 receptors in
neuronal TGF-
 
 
 
 signaling, the expression of ALK5, T
 
 
 
RII,
and ALK1 was determined in primary rat hippocampal neurons
by RT-PCR analysis. Expression of ALK5 mRNA was detected
in the hippocampal neurons as well as in secondary cultures of
rat astrocytes, rat PC12 pheochromocytoma cells, and rat em-
bryonic fibroblasts. T
 
 
 
RII was found to be expressed at low
levels in hippocampal neurons (Fig. 1 A). Astrocytes and rat
embryonic fibroblasts revealed a relatively high expression
level, whereas rat pheochromocytoma PC12 cells that do not
express T
 
 
 
RII (Lutz et al., 2004) served as a negative control.
Interestingly, robust expression levels of ALK1 could be de-
tected specifically in rat hippocampal neurons and PC12 cells;
in contrast, ALK1 mRNA levels were markedly lower in astro-
cytes and fibroblasts (Fig. 1 A). Western blotting experiments
using a polyclonal antibody for ALK1 revealed high ALK1
protein expression levels in hippocampal neurons and to a
lesser extent in astrocytes. HepG2 hepatocytocellular carci-
noma cells, which do not express the ALK1 receptor (Attisano
et al., 1993), served as a negative control (Fig. 1 B). Further ev-
idence for neuronal ALK1 expression was revealed by im-
munofluorescence analysis. Surface-derived immunostaining of
ALK1 protein was detected in hippocampal neurons (Fig. 1 C).
A specific blocking peptide to the ALK1 antibody abolished
the staining. ALK1 immunodetection was also assessed in adult
rat coronal brain sections. Hippocampal and cortical neuronal
cell bodies positive for the neuronal marker NeuN displayed a
substantial ALK1 immunofluorescence. Dendrites and the neu-
ropil revealed a partly punctuated staining as previously de-
scribed for other TGF-
 
 
 
 family receptors (Di Guglielmo et al.,
2003; Fig. 1, D and E). Subsequent confocal immunofluores-
cence analyses, with costaining against glial acidic fibrillary
protein (GFAP), revealed that ALK1 expression was largely
restricted to neuronal cells (Fig. 1 E).
TGF-
 
 
 
1 has been identified as a growth factor/cytokine
up-regulated during brain injury. Therefore, we determined
Figure 1. Neuronal cells express the alternative TGF-  type I receptor ALK1. (A) Expression of ALK5, T RII, and ALK1 mRNA was determined by RT-PCR
analysis in DIV14 primary cultures of rat hippocampal neurons, secondary cultures of astrocytes, as well as REF and PC12 cell lines. GAPDH expression is
shown for normalization purposes. Reaction mixtures without reverse transcriptase served as controls for genomic DNA contamination in all cases (unpub-
lished data). (B) Cell lysates of cultured rat hippocampal neurons, secondary astrocytes, and HepG2 cells were subjected to SDS-PAGE and Western blotting.
The membranes were incubated with the ALK1 antibody, which recognized one specific band;  -tubulin band served as loading control. Experiments in
duplicate yielded comparable results. (C) Immunofluorescence detection of ALK1 protein in cultured rat hippocampal neurons (red). DIV14 hippocampal
cultures were fixed and subsequently incubated with ALK1 antibody. Preincubation of ALK1 antibody with blocking peptide and subsequent immunostaining
served as negative control.  III-Tubulin was used as a neuronal marker (green). (D and E) Immunofluorescence analysis of ALK1 protein expression in coronal
sections of the adult rat brain. Representative cortical areas are shown. Slices were double-labeled with antibodies directed against ALK1 protein (red)
and neuronal nuclear protein NeuN (D, green) or GFAP (E, green) and visualized by confocal microscopy (D) or confocal stack reconstruction (E).
Red and green axes mark the positions of the corresponding perpendicular Z-layers. Bars, 10  m. 
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whether excitotoxic or ischemic injury also influenced the level
of ALK1 mRNA and protein expression. To this end, excito-
toxic neuronal injury was induced in hippocampal neurons by a
brief exposure to the selective glutamate receptor agonist
N-methyl-D-aspartate (NMDA; 300 
 
 
 
M, 5 min). Interestingly,
increased mRNA and protein levels of ALK1 were detected
24 h after the NMDA exposure (Fig. 2, A and B). Treatment
with TGF-
 
 
 
1 did not have a potentiating effect on ALK1 ex-
pression, suggesting that expression of ALK1 is not regulated
by TGF-
 
 
 
1. Increased ALK1 protein expression was also ob-
served in the cortical tissue of rats subjected to focal ischemic
injury induced by middle cerebral artery occlusion (MCAO;
Fig. 2 C). Western blot analysis revealed two specific bands,
possibly corresponding to differentially N-glycosylated forms
of ALK1 (Lamouille et al., 2002). Cortical brain sections of
ischemic rats revealed enhanced neuronal ALK1 staining in
comparison with controls (Fig. 2 D), revealing that ALK1, sim-
ilar to TGF-
 
 
 
1, is up-regulated during brain injury.
 
TGF-
 
 
 
 treatment elicits both ALK5- and 
ALK1-dependent signaling pathways in 
primary rat hippocampal neurons
 
Signaling of TGF-
 
 
 
 superfamily members involves ALK-
mediated phosphorylation of receptor-regulated Smad proteins.
Treatment of hippocampal neurons with TGF-
 
 
 
1 led to transient
induction of Smad2 phosphorylation after 30 min, indicative of
the canonical, ALK5-initiated, Smad2/3-mediated signal trans-
duction pathway (Fig. 3 A; Nakao et al., 1997). Treatment with
bone morphogenetic protein (BMP)-6, which served as a nega-
tive control, did not change the status of Smad2 phosphorylation
Figure 2. Injury-induced up-regulation of
ALK1 receptor in vitro and in vivo. Evaluation
of ALK1 mRNA (A) and protein levels (B) 24 h
after a brief exposure to excitotoxic NMDA
(300  M; 5 min). (A) After the NMDA expo-
sure, cells were treated with 10 ng/ml TGF- 1
or vehicle (2 mg/ml PBS/BSA). 30 cycles of
PCR or Western blot for ALK1 receptor expres-
sion (B) was performed. GAPDH or actin
served as control for equal loading. (C) West-
ern blot analysis of ALK1 protein levels after
ischemia/reoxygenation. Lysates were ob-
tained from lesioned cortex and striatum of ani-
mals subjected to 1 h of ischemia followed by
12 or 24 h of reoxygenation (MCAO). (D)
DAB-immunocytochemistry analysis of MCAO-
induced cortical ALK1 expression. 24 h after re-
oxygenation, lesioned hemispheres were fixed
and stained for ALK1 protein. Bar, 20  m.
Figure 3. TGF-  activates the ALK5 signaling pathway in cultured rat hippocampal neurons and astrocytes. (A) DIV14 rat hippocampal neurons were
treated with 10 ng/ml TGF- 1. (B) In parallel experiments, cultures were incubated with 50 ng/ml BMP-6. Controls received vehicle. At the indicated time
points, whole cell extracts were obtained in TOTEX buffer and analyzed after Western blotting with a P-Smad2 antibody. An unspecific band served as
internal loading control as previously described (Goumans et al., 2002). A duplicate experiment yielded comparable results. (C and D) Dual-luciferase
reporter gene analysis for the ALK5 pathway-responsive (CAGA)12-luc. 24 h after transfection of DIV6 hippocampal neurons, cells were treated with the
indicated cytokines and lysed after 24 h of further incubation. In D, cotransfection was performed with the indicated plasmids. Luciferase responsiveness
was normalized to the cotransfected RL-TK-luc. Data are means   SEM from n   4–6 cultures. *, P   0.05 to control. Experiments were performed in
duplicate with similar results. (E) Cultured secondary astrocytes were incubated with 10 ng/ml TGF- 1 as indicated. Subsequent procedures were conducted
as specified in A and B. 
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(Fig. 3 B). TGF-
 
 
 
1 treatment also induced significant Smad2
phosphorylation in cultured secondary astrocytes (Fig. 3 E). To
examine the downstream activation of the Smad2/3-evoked
transcriptional response in neurons, we used a Smad3-respon-
sive (CAGA)
 
12
 
-luciferase reporter gene assay (Dennler et al.,
1998). Transient transfection experiments revealed that TGF-
 
 
 
1 significantly induced the activity of the (CAGA)
 
12
 
-luciferase
reporter gene (Fig. 3 C), whereas BMP-6 did not affect reporter
gene expression. Constitutively active forms of ALK5 and
ALK1 receptors have been shown to transduce signaling in a
ligand-independent manner (Goumans et al., 2002). We co-
transfected hippocampal neurons with plasmids encoding caALK5
and caALK1, and examined their influence on (CAGA)
 
12
 
-
luciferase reporter activity. Transient transfection of caALK5,
but not caALK1, was able to mimic the effect of TGF-
 
 
 
1 on
(CAGA)
 
12
 
-luciferase reporter activity (Fig. 3 D).
The alternative receptor ALK1 has been reported to
transduce TGF-
 
 
 
 signaling in primary endothelial cells via a
Smad1-dependent pathway (Chen and Massague, 1999; Gou-
mans et al., 2002). Interestingly, phosphorylation of Smad1
protein occurred rapidly upon exposure of hippocampal neu-
rons to TGF-
 
 1 (Fig. 4 A). In contrast to Smad2 phosphoryla-
tion (Fig. 3 A), this activation exhibited a stable plateau for up
to 24 h (Fig. 4 A). A similar response was observed in neurons
treated with BMP-6 (50 ng/ml), which served as a positive con-
trol. In agreement with the low expression of ALK1 (Fig. 1, A
and B), cultured astrocytes exhibited only transient and modest
levels of phosphorylated Smad1 in comparison to neurons (Fig.
4 B). We additionally confirmed Smad1 signaling by analysis
of Smad1 nuclear translocation after TGF- 1 (10 ng/ml) treat-
ment. After a 3-h incubation period, a statistically significant
increase in nuclear Smad1 immunostaining became apparent
(Fig. 4 C).
Next, we sought to further confirm the role of ALK1 in
neuronal TGF-  signaling. Recent evidence suggests that upon
ligand binding, ALK1 associates with ALK5 and T RII to
form a kinase-active heteromeric complex, thereby requiring a
functional ALK5 receptor for signal transduction (Goumans et
al., 2003). Brief stimulation with TGF- 1 indeed led to in-
creased coimmunoprecipitation of ALK1 with ALK5 in cul-
tured neurons (Fig. 4 D). The synthetic inhibitor SB-431542
has previously been shown to block ALK5- and ALK1-depen-
dent Smad phosphorylation (Inman et al., 2002; Goumans et
al., 2003). Consequently, we evaluated ALK1-directed Smad1
phosphorylation by using SB-431542. Preincubation with the
inhibitor repressed TGF- 1–induced phosphorylation of Smad1
(Fig. 4 E).
TGF- 1 treatment induces neuronal I B-  
phosphorylation and increases DNA 
binding of the p65 NF- B subunit
We have previously shown that treatment of hippocampal
neurons with TGF- 1 increased the expression of the NF- B
target genes Bcl-2 and Bcl-xL (Prehn et al., 1994, 1996).
Therefore, we were interested to determine if TGF- 1 can induce
the activation of the NF- B pathway in neurons. Phosphorylation
Figure 4. TGF- 1 induces ALK1 hetero-oligomerization with ALK5 and subsequent phosphorylation of Smad1. DIV14 hippocampal neurons (A) or
secondary astrocytes (B) were incubated with the indicated cytokines, lysed, and subjected to SDS-PAGE and blotting (as described in Fig. 3 A).
Membranes were incubated with P-Smad1 antibody. An unspecific band served as internal loading control as previously described (Goumans et al.,
2002; compare B to Fig. 3 E, stripped membrane). The experiment was performed in triplicate with comparable results (A). (C) Immunofluorescence detection
of Smad1 translocation to the nucleus and its quantitative evaluation in cultured rat hippocampal neurons. Neurons were treated with 10 ng/ml TGF- 1
for 3 h. After fixation and permeabilization, localization of Smad1 protein was determined by anti-Smad1 antibody (red). Neuronal nuclei were stained
using NeuN antibody (green). Note the increase in Smad1 nuclear patches occurring in TGF- 1–treated cells, resembling neurons treated with BMP-4
(Angley et al., 2003). Bars, 10  m. Quantification of nuclear translocation was determined without knowledge of the respective treatments. A total of
350–450 cells were counted in three separate experiments. Data are means   SEM; *, P   0.05. (D) Coimmunoprecipitation analysis of TGF- 1 induced
ALK5/ALK1 receptor complexes. Cortical neurons (DIV14) were treated with10 ng/ml TGF- 1 for 15 min. After immunoprecipitation with ALK5 antibody,
SDS-PAGE and Western blotting were conducted as described in Fig. 3 A. Membranes were incubated with the anti-ALK1 antibody. Immunodetection of
light-chain (LC) by anti–rabbit antibody served as control. (E) Hippocampal neurons were incubated with 10 ng/ml TGF- 1 for 1 h. 30 min of preincu-
bation with 5  M SB-431542 were performed as indicated.TGF- 1 ACTIVATES NEURONAL NF- B VIA ALK1 • KÖNIG ET AL. 1081
of serine 32 and 36 of the inhibitory I B-  and its subsequent
degradation have been recognized as one of the key steps in
NF- B activation (Ghosh and Karin, 2002). TGF- 1 induced
a rapid and persistent accumulation of serine32-phosphory-
lated I B-  in hippocampal neurons (Fig. 5 A, top), which
correlated with a slow decline in I B-  levels (Fig. 5 A, bottom).
Next, we examined the effect of TGF- 1 on NF- B–dependent
gene expression using a  B-dependent luciferase reporter
assay. It is important to note in this context that neurons ex-
hibit constitutively high levels of baseline NF- B activity
(Kaltschmidt et al., 1994). Of note, stimulation with TGF- 1
for 24 h further increased  B-dependent reporter gene expres-
sion (Fig. 5 B). Interestingly, preincubation with SB-431542
suppressed TGF- 1–stimulated NF- B activity toward the
baseline level. Exposure to TNF-  (Fig. 5 B) and repression
of NF- B liberation by overexpression of I B-  protein (un-
published data) served as positive and negative controls, re-
spectively. Treatment of hippocampal neurons with TGF- 1
also resulted in a marked increase in Bcl-xL protein levels,
and this effect could be blocked by preincubation with SB-
431542 (5  M; Fig. 5 C). Subsequently, we analyzed the time
course of NF- B induction in gelshift experiments. TGF- 1
treatment led to a substantial increase in  B-DNA binding
after 4 and 24 h post-treatment (Fig. 5 D). Increasing evi-
dence suggests that different subunit compositions of activated
NF- B complexes regulate specific subsets of NF- B target
genes in a time- and stimulus-dependent fashion (Hoffmann
et al., 2003; Saccani et al., 2003). To identify the NF- B
subunit composition induced by TGF- 1 in hippocampal
neurons, we conducted supershift experiments. Antibodies
directed against p65 were able to supershift the TGF- 1–
induced NF- B–DNA complex, whereas antibodies to other
subunits (p50, p52, c-Rel, and RelB) caused no discernible
shift (Fig. 5 E).
The constitutively active mutant of 
ALK1 mimics TGF- –dependent Smad1 
phosphorylation, NF- B activation, and 
neuroprotection
To reveal whether ALK1 or ALK5 mediate NF- B activation
in hippocampal neurons, we cotransfected hippocampal neu-
rons with caALK1 and caALK5 in combination with p65-
EGFP. The fusion protein p65-EGFP has been shown to be a
valuable tool in visualizing p65/RelA nuclear translocation
(Meffert et al., 2003), which is a prerequisite for NF- B–
dependent transcription (Ghosh and Karin, 2002). To confirm
p65-EGFP localization in hippocampal neurons, costaining
with the neuronal marker  III-tubulin was used. Interest-
ingly, caALK1 led to a markedly increased nuclear accumu-
lation of p65-EGFP in the hippocampal neurons 24 h after
Figure 5. TGF- 1 activates NF- B in hippocampal neurons. (A) DIV14 cultured rat hippocampal neurons were treated with 10 ng/ml TGF- 1 as indicated.
Whole cell lysates were subjected to SDS-PAGE and Western blotting. Serine-32 phosphorylated I B-  was immunodetected by incubation of membranes
with the polyclonal P-I B-  antibody (top). For evaluation of overall I B-  levels, membranes were stripped and reprobed with a rabbit polyclonal I B- 
antibody (bottom). (B) Dual-luciferase NF- B reporter gene assay. After transfection of NF- B-luc and RL-TK-luc, cells were allowed to recover for 24 h.
30 min of preincubation with 5  M SB-431542 preceded 24 h of exposure to TGF- 1. 10 ng/ml TNF-  treatment served as positive control. Data are
means   SEM of n   8–16 treatments in three independent, normalized, and pooled experiments. *, #, P   0.05 compared with control or TGF- 1
treatment, respectively. (C) Western blot analysis for Bcl-xL protein content after 24 h of treatment with TGF- 1 in primary rat hippocampal neurons. Cells
were preincubated for 30 min with 5  M SB-431542 as indicated. After stripping,  -tubulin served as loading control. (D) Time course of enhanced  B-DNA
binding after TGF- 1 treatment as revealed by gelshift experiments. Lysates were incubated with  
32P-ATP–labeled  B-consensus oligonucleotide (for com-
parative reasons, identical lysates as for the experiment depicted in Fig. 4 A were used). Experiments in triplicate revealed comparable results. Addition
of I B-  protein served as control for  B-binding specificity. The asterisk marks the NF- B dimer-specific band. (E) Supershift analysis of TGF- 1–induced
NF- B complexes. After stimulation of hippocampal neurons with TGF- 1, equal amounts of lysates were analyzed by incubation with antibodies to the re-
spective NF- B subunits before incubation with labeled NF- B oligonucleotide as denoted. Supershifted bands (ss) where visualized using autoradiography.
A duplicate experiment yielded comparable results. (C and E) White lines indicate that intervening lanes have been spliced out.JCB • VOLUME 168 • NUMBER 7 • 2005 1082
transfection. In contrast, caALK5 alone did not induce sig-
nificant p65-EGFP translocation (Fig. 6 A). We further de-
termined whether or not ectopic expression of caALK1 was
sufficient to potently stimulate NF- B reporter gene activity.
Expression of caALK1 induced a potent increase in  B re-
porter gene transcription, whereas caALK5 could not elicit
a substantial increase compared with control transfections
(Fig. 6 B).
The inhibitory Smad6 protein specifically interferes
with Smad1/5-mediated signal transduction (Fig. S1, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200407027/
DC1; Hata et al., 1998; Zhao et al., 2000). Transfection of
caALK1 substantially elevated nuclear immunofluorescence
of phosphorylated Smad1 in the hippocampal neurons. In con-
trast, cotransfection of caALK1 with Smad6 abolished the ele-
vated nuclear immunofluorescence of phosphorylated Smad1
(Fig. 6 C).
To test whether or not ALK1 activation is required for
TGF- 1–induced NF- B activation, we cotransfected hippo-
campal neurons with the inhibitory Smad6 protein and performed
NF- B reporter gene assays in vehicle and TGF- 1–treated
hippocampal neurons. Interestingly, the induction of NF- B
activity by TGF- 1 could efficiently be blocked by Smad6
cotransfection (Fig. 6 D). In line with these observations,
cotransfection of Smad6 protein with caALK1 also led to sig-
nificant abrogation of caALK1-evoked NF- B activation (Fig.
6 E), whereas transfection of Smad6 alone exhibited no signifi-
cant change in  B-dependent reporter gene expression (Fig. 6,
D and E).
Finally, we tested if caALK1 is able to also mimic
TGF- 1–mediated neuroprotection. Preincubation with TGF-
 1 has previously been shown to rescue neurons from ex-
citotoxic, ischemic, and oxidative stress–induced cell death
(Henrich-Noack et al., 1996). Cortical neurons were trans-
Figure 6. ALK1 mediates TGF- –induced NF- B activity, whereas overexpression of Smad6 abrogates this effect. (A) Primary rat hippocampal neurons
were transfected with p65-EGFP and cotransfected with the constitutively active ALK encoding plasmids. 24 h after transfection, cells were fixed and stained
with antiserum to neuronal marker  III-tubulin (red). Localization of p65-EGFP (green) was evaluated using confocal microscopy as exemplified in the figure.
In preliminary experiments, the amount of p65-EGFP was titrated down to a level still showing a homogeneous somatic distribution in a majority of neurons.
Functionality of p65-EGFP was proven by its ability to increase NF- B-luciferase reporter gene (unpublished data). Bars, 10  m. (B) Dual-luciferase reporter
gene assay for enhanced NF- B activity after cotransfection of constitutively active TGF-  type I receptors. Hippocampal neurons were transfected on DIV6
with NF- B-luciferase and RL-TK-luciferase reporter gene constructs, as well as cotransfected with either caALK1, caALK5, or pcDNA vector. 48 h after trans-
fection, cells were lysed and dual-luciferase assay was performed. (C) Confocal immunofluorescence of increased nuclear accumulation of phosphorylated
Smad1 in caALK1-transfected neurons. Hippocampal neurons were transiently cotransfected with pEGFP-N1 (green) and either control pcDNA, caALK1, or
Smad6 expression vectors as indicated. 24 h after transfection, cells were fixed and immunostained with anti-P-Smad1 antibody (red). Arrowheads indicate
cotransfected cells with increased versus decreased nuclear P-Smad1 staining. Bars, 10  m. (D) Hippocampal neurons were transfected with the NF- B-
luciferase reporter plasmids and cotransfected with control or Smad6 vector after which they were allowed to recover from transfection for 24 h. Subse-
quent treatment with TGF- 1 was performed for a period of 24 h. (E) NF- B-luciferase reporter gene transfected neurons were cotransfected with the indicated
plasmids. 48 h after transfection, a dual-luciferase assay has been performed. Experiments performed in duplicate yielded similar results. The data represent
NF- B activity in relation to control   SEM from n   6 wells. *, P   0.05 as compared with control or bracketed treatment.TGF- 1 ACTIVATES NEURONAL NF- B VIA ALK1 • KÖNIG ET AL. 1083
fected with caALK1 and caALK5 expression vectors and ex-
posed to the nitric oxide (NO)–generating agent S-nitroso-
cysteine (SNOC; 30  M; Henrich-Noack et al., 1996). NO is
an important mediator of both excitotoxic and ischemic neu-
ronal injury (Dawson et al., 1991; Ayata et al., 1997). Indeed,
overexpression of caALK1 in neurons conferred a substan-
tially enhanced resistance against SNOC-induced cell death,
whereas neurons transfected with caALK5 were not pro-
tected (Fig. 7 A).
Discussion
In the present work, we demonstrate constitutive expression
and stress-induced up-regulation of the novel TGF-  type I re-
ceptor ALK1 in neurons. Furthermore, we provide evidence
that TGF- 1 and ALK1 activate the transcription factor NF- B
in a manner depending on an intact Smad1/5 pathway. Consti-
tutive and inducible NF- B activity has been shown to contrib-
ute to neuronal survival and to protect the nervous system from
various stress conditions (Kaltschmidt et al., 1994; Mattson et
al., 2000). Our data, together with previous work on TGF- 1–
mediated neuroprotection, suggest that the concomitant up-reg-
ulation of TGF- 1 and ALK1 expression during brain injury
may be an essential part of an endogenous response aimed to
limit the consequences of metabolic, toxic, or traumatic injury
to the nervous system.
Although microglia and macrophages appear to be a ma-
jor source of TGF- 1 during brain injury (Lindholm et al.,
1992), the corresponding ALK1 receptor is expressed at high
levels particularly in neurons (Figs. 1 and 2). This finding
suggests the existence of a framework for a direct crosstalk
between activated microglia and neurons during brain injury.
Early studies on TGF-  signaling described ALK1 as an alter-
native type I receptor for TGF-  (Franzen et al., 1993). A
physiological role of TGF- 1–induced ALK1 activation has
so far only been described in vascular endothelial cells (Oh et
al., 2000). TGF- 1 signaling in vascular endothelial cells in-
volves the canonical ALK5-mediated Smad2/3 pathway, as
well as ALK1-directed phosphorylation of Smad1/5 (Gou-
mans et al., 2002). This pathway was initially described as a
BMP-restricted pathway, transduced through distinct BMP re-
ceptor subsets (Shi and Massague, 2003). In endothelial cells,
the intricate balance between ALK1 and T RI/ALK5 sig-
naling orchestrates epithelial to mesenchymal transition in
TGF-  regulation of angiogenesis (Oh et al., 2000; Goumans
et al., 2002). Our work demonstrates a simultaneous TGF- 1
activation of the ALK5/Smad2/3 and the ALK1/Smad1/5 path-
way in the hippocampal neurons. TGF- 1 induced an increase
in ALK5-mediated phosphorylation of Smad2, as well as an
increase in Smad3-specific (CAGA)12-luciferase reporter gene
activity. Interestingly, phosphorylation of Smad2 in the hip-
pocampal neurons was only transient, and the expression
level of ALK5 was moderate compared with that observed in
astrocytes or fibroblasts. Moreover, in contrast to astrocytes,
ALK1 expression and ALK1-dependent Smad1 phosphoryla-
tion by TGF- 1 was much more pronounced and persistent in
neurons, suggesting that ALK1 may be of greater importance
in neuronal TGF- 1 signaling. Hence, we propose a model in
which the relative balance of ALK1 and ALK5 expression
may determine the composition of activated receptor com-
plexes in a competitive manner, thus leading to transduction of
TGF- –induced signals into a predominant downstream path-
way (Fig. 7 B).
Activation of the Smad1 pathway by TGF- 1 in neurons
was associated with activation of NF- B. Interestingly, a non-
phosphorylatable mutant of Smad1 has been shown to prevent
Smad1-dependent proteasomal degradation of the Smad nu-
clear interacting protein 1, which negatively regulates the NF- B
pathway by sequestration of the p65 coactivator CBP/p300
Figure 7. ALK1-initiated signaling confers neuroprotection. (A) Expression
of the constitutively active ALK1 receptor results in increased resistance to
oxidative stress. Cultured primary cortical neurons were cotransfected with
caALK1, caALK5, or control vector together with EGFP. After transfer to
antioxidant-depleted media, cultures were treated with 30  M of the NO-
donator SNOC. 24 h after treatment, cultures were incubated with PI for
evaluation of cell death. 910–1226 EGFP-positive neurons were counted
and depicted as means   SEM of n   3–6 treatments in two normalized
and pooled experiments. (B) Proposed schematic model for TGF- –induced
downstream signaling in hippocampal neurons. TGF-  binds to T RII,
which recruits and activates the type I receptors. ALK1 and ALK5 phosphor-
ylate their downstream targets Smad1/5 or Smad2/3, respectively. More-
over, Smad6 specifically inhibits the ALK1-induced pathway. Smad1/5-
involving signaling is able to evoke NF- B activation, whereas Smad2/3
induction results in activation of the classical TGF-  target genes.JCB • VOLUME 168 • NUMBER 7 • 2005 1084
(Wang, 2003). Of note, enhanced NF- B activity in neurons
after TGF- 1 stimulation was associated with the activation
of the p65 NF- B subunit. The formation of p65/p65 ho-
modimers has been implicated in NF- B signaling (Ganchi et
al., 1993). Several studies have substantiated the concept that
distinct NF- B subunit compositions coordinate the activation
of distinct subsets of NF- B target genes (Hoffmann et al.,
2003; Saccani et al., 2003). We could demonstrate a potent
TGF- 1–dependent up-regulation of the antiapoptotic protein
Bcl-xL. Because Bcl-x has previously been identified as a p65
target gene in neurons (Bhakar et al., 2002), induction of Bcl-
xL via NF- B might constitute an integrative mechanism by
which neuroprotective cytokines such as TGF- 1 and NGF
(Bui et al., 2001) promote survival of neurons. Overexpression
of the inhibitory Smad6 protein was able to abrogate the ef-
fects of TGF- 1 and Smad6 on NF- B activation. Although
Smad7 has been implicated in blockade of Smad2/3 as well as
Smad1/5-induced signaling (Shi and Massague, 2003), Smad6
has been shown to specifically inhibit Smad1/5-mediated cel-
lular responses (Fig. S1; Hata et al., 1998; Zhao et al., 2000).
Interestingly, NF- B has been shown to up-regulate Smad7
expression (Bitzer et al., 2000), which may actually lead to a
suppression of the canonical, ALK5-mediated TGF- 1 signal-
ing pathway in neurons. In addition to ALK1-mediated sur-
vival signaling in neurons, the ALK5/Smad2/3 pathway may
promote specific astroglial responses such as up-regulation of
plasminogen activator inhibitor type 1 (Buisson et al., 1998),
and thus might contribute to TGF- –induced protective tissue
responses during brain injury.
TGF- 1 and TGF- 3 have been identified as ligands to
the ALK1 receptor, whereas TGF- 2 shows very little affinity
to this receptor (Lux et al., 1999). It is interesting to note in this
context that TGF- 1 and TGF- 3 have suggested to be more
potent in protecting neurons from hypoxic and excitotoxic in-
jury than TGF- 2 (Prehn et al., 1993b), suggesting nonredun-
dant functions of the TGF-  family members. Similar to effects
of TGF- s in hepatocytes and immune cells, TGF- s have also
been shown to be capable of inducing or potentiating cell death
in neurons (Prehn and Krieglstein, 1994; de Luca et al., 1996).
Likewise, immunoneutralization of endogenous TGF- s has
been shown to reduce ontogenetic cell death in a subset of neu-
ronal populations (Krieglstein et al., 2000). Possibly, the con-
flicting reports on protective versus death-promoting abilities
of the TGF- s can directly be explained by the balance be-
tween ALK1 and ALK5 receptor-related signaling cascades,
differences in ALK1 and ALK 5 receptor expression, as well as
potentially by nonredundant biological activities of the three
isoforms. In support of the latter, TGF- 2 was recently identi-
fied as a potential inhibitor of neuronal survival signaling in an
unbiased genomic screen approach (Kaltschmidt and Kalt-
schmidt, 2001). TGF- s may hence enable the nervous system
to fine-tune both developmental processes and brain responses
to injury. From a teleological point of view, TGF- s may join
other neurotrophic factors such as NGF in their intricate ability
to influence cell survival and cell death decisions by activation
of different subsets of receptors (Barrett and Bartlett, 1994;
Carter et al., 1996).
Materials and methods
Materials
Human recombinant TGF- 1 and BMP-6 were obtained from R&D Systems
and TNF-  came from Biosource International. SB-431542 and tetrodo-
toxin were obtained from Tocris Cookson Ltd. All other chemicals were ob-
tained from Sigma-Aldrich or Applichem. Cell culture media and supple-
ments came from Invitrogen unless otherwise indicated.
Cell culture
Rat embryonal fibroblast (REF52), hepatoblastoma (HepG2), as well as
rat pheochromocytoma (PC12) cells, and astrocytes were grown in DME
supplemented with 10% FCS and the antibiotic mixture of 100 U/ml peni-
cillin and 100  g/ml streptomycin. Rat hippocampal neurons were pre-
pared from neonatal (P0–P1) Wistar rats and maintained as described
previously (Kögel et al., 2004). Cortical neurons were prepared as previ-
ously outlined (Dawson et al., 1991) and maintained in Neurobasal me-
dium with 2% B-27 supplement, 2 mM L-glutamine, and the antibiotic mix-
ture. Neuronal cultures received cytosine- -D-arabinofuranoside (CAF, 1  M;
Sigma-Aldrich) beginning on days in vitro (DIV) 2 to suppress glial prolifer-
ation. Secondary cultures of astrocytes from the cortex of neonatal Wistar
rats (P1) were prepared as described previously (Kögel et al., 2004).
After 10 d in culture, cells were passaged and kept in CAF-free hippocam-
pal medium for treatment with TGF- 1. Cultures were maintained at 37 C
in a humidified atmosphere of 95% air and 5% carbon dioxide. Animal
care followed official governmental guide lines.
RT-PCR
Extraction of total cellular RNA, reverse-transcription, and PCR was per-
formed as previously described (Kögel et al., 2004). Primer sequences
and amplification procedures are available in Table S1 (available at
http://www.jcb.org/cgi/content/full/jcb.200407027/DC1).
Immunofluorescence analyses and immunocytochemistry
Cells were fixed with 4% PFA and permeabilized by PBS/0.1% Triton
X-100. For ALK1 immunofluorescence analyses, the prior permeabilization
step was omitted. Nonspecific antibody binding was blocked by PBS/5%
horse serum/0.3% Triton X-100 for 30 min at RT in all cases. Antibodies
were diluted in blocking buffer. Incubation times followed general proce-
dures. ALK1 was detected using a goat polyclonal anti-ALK1 antibody
(D-20; Santa Cruz Biotechnology, Inc.), and blocking peptide (19546 P;
Santa Cruz Biotechnology, Inc.) was used at 20-fold excess by weight. Af-
ter permeabilization, mouse mAbs for neuronal marker proteins  III-tubu-
lin (Promega) or anti-NeuN (Chemicon), the glial fibrillary acidic protein
anti-GFAP (Promega), as well as a rabbit polyclonal anti-Smad1 anti-
body (Upstate Biotechnology), and a rabbit polyclonal antiphosphorylated
Smad1 antibody (Upstate Biotechnology) were used to detect the respec-
tive proteins. Secondary antibodies used were either biotin-conjugated
anti–goat, anti–rabbit, or anti–mouse IgG (Vector Laboratories). Subse-
quent incubation was conducted with streptavidin-conjugated Oregon
green or Texas red (Molecular Probes). Coronal brain sections (provided
by C. Schultz, University Clinics Frankfurt, Frankfurt, Germany) were ob-
tained from female adult rats perfused transcardially with cold 4% PFA un-
der anesthesia. DAB histochemistry followed general procedures. Sections
or cells were mounted with Permafluor (Immunotech). Light or immunofluo-
rescence microscopy was performed at RT using an inverted microscope
(Eclipse TE2000S; Nikon) and a 60  oil immersion objective (NA 1.40;
Nikon). Texas red or Oregon green/EGFP-fluorescence was observed us-
ing the following optics: excitation, 540–580 nm; dichroic mirror, 595
nm; emission, 600–660 nm; or excitation, 465–495; dichroic mirror,
505; emission, 515–555 nm, respectively. Confocal images and stacks
were acquired on a microscope (model LSM 510; Carl Zeiss MicroImag-
ing, Inc.) with a krypton/argon and helium/neon laser and a 63  oil im-
mersion objective (NA 1.40; Carl Zeiss MicroImaging, Inc.). For p65-EGFP
or Oregon green, the excitation/emission filter was 488/505–530 nm.
For Texas red and propidium iodide (PI) staining, excitation/emission was
543/560–615 nm.
Immunoprecipitation analysis, SDS-PAGE, and Western blotting
Cell lysis for Western blotting was performed using TOTEX (Kögel et al.,
2004) or RIPA lysis buffer, as indicated. For immunoprecipitation analy-
sis, cells were solubilized with PBS containing 1% (vol/vol) Triton X-100,
5 g/liter sodium deoxycholate, and 1 g/liter SDS. Immunoprecipitation
was performed using rabbit polyclonal anti-T RI–conjugated agarose
beads (V-22; Santa Cruz Biotechnology, Inc.) according to the manufac-
turer’s instructions. All lysis buffers contained protease inhibitors (ProteaseTGF- 1 ACTIVATES NEURONAL NF- B VIA ALK1 • KÖNIG ET AL. 1085
inhibitor cocktail; Sigma-Aldrich). SDS-PAGE, Western blotting, and strip-
ping procedures were conducted as described previously (Bui et al., 2001).
Immunodetections were performed with a goat polyclonal anti-ALK1 anti-
body (D-20; Santa Cruz Biotechnology, Inc.), a monoclonal anti-rat Bcl-x
antibody (B22620; Transduction Laboratories), and a mouse monoclonal
anti– -tubulin antibody (Sigma-Aldrich), as well as rabbit polyclonal anti-
bodies against serine 465/467-phosphorylated Smad2 (P-Smad2; Upstate
Biotechnology), serine 463/465-phosphorylated Smad1 (P-Smad1; Upstate
Biotechnology), serine 32-phosphorylated I B-  protein, and total I B- 
(Cell Signaling Technology) according to the manufacturer’s instructions.
Electrophoretic mobility shift assay (Gelshift)
Gelshift analysis was performed as described previously (Kögel et al.,
2004). For supershift experiments, the respective antibodies correspond-
ing to NF- B subunits (Santa Cruz Biotechnology, Inc.) were added to the
mixture before the  
32P-ATP–labeled NF- B consensus oligonucleotide
(Promega). Samples were separated on 4% nondenaturing gels and ana-
lyzed by autoradiography.
Transient transfection experiments and analysis of reporter gene activity
For reporter gene studies, hippocampal neurons were transfected in 24-
well plates (Becton Dickinson) using the Lipofectamine 2000 (Invitrogen)
transfection reagent following the manufacturer’s protocol. Transfection effi-
ciency, revealed by cotransfection experiments with pEGFP-N1 (CLON-
TECH Laboratories, Inc.) ranged between 10–30% in control experiments.
Transfection mixes contained 0.3  g/well of pcDNA 3.1 (Invitrogen),
pcDNA-ALK1 (Q201D)/caALK1 (provided by C.-H. Heldin, Ludwig Insti-
tute for Cancer Research, Uppsala, Sweden), pcDNA-ALK5 (T204D)/
caALK5, or pcDNA-Smad6/Smad6 (provided by M. Kawabata, The Can-
cer Institute, Tokyo, Japan) expression vector. Cells were cotransfected with
0.3  g/well of a plasmid containing six tandem repeats of the  B en-
hancer element upstream of the coding sequence of the Firefly-luciferase
(NF- B-luc) or a plasmid encoding TGF-  responsive (CAGA)12-luciferase
(Dennler et al., 1998; provided by Glaxo-Wellcome, Les Ulis, France)
along with 0.05  g of a plasmid coding for the Renilla-luciferase (phRL-TK-
luc; Promega) as transfection control for normalization in dual-luciferase
assays. Dual-Luficerase reporter assay was performed following the manu-
facturer’s protocol (Promega). For immunofluorescence analysis, rat hippo-
campal neurons were transfected with a plasmid encoding p65 fused to the
fluorescent EGFP (p65-EGFP; provided by M. Rowe and E. Floettmann, Uni-
versity of Wales College of Medicine, Cardiff, UK) or pEGFP-N1 (CLON-
TECH Laboratories, Inc.), respectively, together with the T RI mutants.
Induction of neuronal injury and evaluation of cell death
Induction of excitotoxic neuronal injury was performed as described previ-
ously (Kögel et al., 2004). For the induction of NO-mediated toxicity, cul-
tured cortical neurons were transfected with the respective T RI receptor
mutants, together with pEGFP-N1 as described for transient transfection
experiments. After transfection, every 12 h, half of the medium was ex-
changed with the conditioned neurobasal medium containing antioxidant-
free B27 (Invitrogen) to slowly deplete antioxidants. 36 h after transfec-
tion, all media were replaced by the conditioned antioxidant-free media
and the freshly prepared NO-generating agent SNOC (Lei et al., 1992)
was added to the culture medium at 30  M as previously described (Hen-
rich-Noack et al., 1996). Aged SNOC, left at RT for 2 d, served as con-
trol. 24 h after toxicity induction, cells were stained with 2  g/ml PI and
immediately assayed for cell death. PI/EGFP-positive neurons were counted
as dead versus total number of EGFP-positive neurons.
Induction of temporal cerebral ischemia by MCAO
Experiments were performed on adult male Sprague-Dawley rats (R. Janvier
Breeding Center, Le Genest-St Isle, France) under anesthesia during sur-
gery according to the appropriate European Directives. Temporary focal
cerebral ischemia was induced by occlusion of the right middle cerebral
artery by use of the intraluminal filament technique (Longa et al., 1989).
A nylon thread was inserted to the origin of the middle cerebral artery and
removed 60 min later to allow reperfusion. For sham-operated animals,
the nylon thread was immediately removed. Rat brain homogenates en-
riched for the lesioned areas containing cortex and striatum were ana-
lyzed by Western blotting.
Statistics
Data are presented as means   SEM. For statistical comparison, one-way
ANOVA followed by Tukey’s test was used. Mann-Whitney U-test was
used for evaluation of nonparametric data. P values  0.05 were consid-
ered to be statistically significant.
Online supplementary material
Table S1shows primer sequences and amplification procedures as con-
ducted for RT-PCR experiments. Additional reporter gene assays have
been conducted to confirm specific blocking of the ALK1-induced NF- B
pathway by Smad6 (Fig. S1). Online supplemental material is available at
http://www.jcb.org/cgi/content/full/jcb.200407027/DC1.
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